Free tool
FAERS Monitor: Semglee
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761201 or its brand name (Semglee, Insulin Glargine-Yfgn). Reports on generic versions are filed under their own applications.
Reports
22,377
Serious
19,546
87% of reports
Hospitalization
11,755
Death reported
2,448
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hypoglycaemia1,741
- blood glucose increased1,627
- acute kidney injury1,066
- dyspnoea1,005
- nausea971
- off label use957
- hyperglycaemia952
- drug ineffective923
- diarrhoea919
- vomiting856
- fatigue828
- condition aggravated768
- fall688
- dizziness681
- asthenia676
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 99 |
| 2005 | 108 |
| 2006 | 89 |
| 2007 | 111 |
| 2008 | 169 |
| 2009 | 191 |
| 2010 | 299 |
| 2011 | 360 |
| 2012 | 263 |
| 2013 | 403 |
| 2014 | 420 |
| 2015 | 617 |
| 2016 | 722 |
| 2017 | 877 |
| 2018 | 2,418 |
| 2019 | 2,583 |
| 2020 | 1,570 |
| 2021 | 1,584 |
| 2022 | 1,964 |
| 2023 | 1,844 |
| 2024 | 2,236 |
| 2025 | 1,721 |
| 2026 | 1,728 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,031,782 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypoglycaemiaSignal | 1,741 | 35.0 | 33.4 | 55,463 |
| hyperglycaemiaSignal | 952 | 25.2 | 23.7 | 21,550 |
| blood glucose increasedSignal | 1,627 | 8.2 | 7.8 | 10,248 |
| acute kidney injurySignal | 1,066 | 6.6 | 6.2 | 5,047 |
| condition aggravatedSignal | 768 | 2.4 | 2.2 | 619 |
| fall | 688 | 1.9 | 1.8 | 319 |
| vomiting | 856 | 1.7 | 1.6 | 258 |
| asthenia | 676 | 1.7 | 1.6 | 193 |
| dyspnoea | 1,005 | 1.7 | 1.6 | 276 |
| diarrhoea | 919 | 1.3 | 1.3 | 81 |
| dizziness | 681 | 1.3 | 1.2 | 43 |
| nausea | 971 | 1.2 | 1.1 | 20 |
| off label use | 957 | 1.0 | 1.0 | 1 |
| fatigue | 828 | 1.0 | 0.9 | 0 |
| drug ineffective | 923 | 0.7 | 0.6 | 174 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.